Yaz ad gets FDA-OK make-over
Executive Summary
Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August
You may also be interested in...
Advertising Citations Reach Record High: Another Way To Regulate Pharma?
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.